{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:19:05Z","timestamp":1767205145488,"version":"build-2238731810"},"reference-count":34,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Myrtle I. Harkness Hussein Pacha Endowment"},{"name":"Lahey Hospital and Medical Center"},{"name":"Beth Israel Lahey Health"},{"name":"Office of Medical Education, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA, USA"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Life"],"abstract":"<jats:p>This study investigated whether the interval of monitoring at-risk, fellow eyes of patients with unilateral neovascular age-related macular degeneration (nAMD) has any bearing on the severity of the disease at the time of diagnosis. The study comprised a retrospective, cross-sectional comparative case series of treatment-na\u00efve eyes in patients who were diagnosed sequentially with nAMD. We compared the visual acuity (VA) and central macular thickness (CMT) of patients who were actively receiving intravitreal injections (IVIs) of anti-vascular endothelial growth factor (anti-VEGF) agents at the time of second eye diagnosis with the VA and CMT of patients who had ceased treatment in their first eye because of reaching end-stages of disease. Intervals of visits and frequency of monitoring the macula of fellow eyes by means of optical coherence tomography (OCT) were abstracted from the medical record. We found that the at-risk fellow eyes of patients who had stopped treatment for nAMD in their first eye prior to fellow eye conversion were monitored significantly less frequently than the fellow eyes of patients who continued to receive treatment at the time of second eye diagnosis. Despite less frequent monitoring, VA and CMT were similar at the time of fellow eye diagnosis for both groups.<\/jats:p>","DOI":"10.3390\/life13020385","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T01:35:45Z","timestamp":1675128945000},"page":"385","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration"],"prefix":"10.3390","volume":"13","author":[{"given":"Oluchukwu","family":"Onwuka","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA 01805, USA"},{"name":"Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackson L.","family":"Saddemi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA 01805, USA"},{"name":"Cooper Medical School, Rowan University, Camden, NJ 08103, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7088-7303","authenticated-orcid":false,"given":"Fatma Sema","family":"Akkan Aydo\u011fmu\u015f","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA 01805, USA"},{"name":"Ophthalmology Department, Ankara Sehir Hastanesi, \u00dcniversiteler, \u00c7ankaya, 06800 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia C.","family":"Lasalle","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA 01805, USA"},{"name":"Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5504-812X","authenticated-orcid":false,"given":"David J.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA 01805, USA"},{"name":"Department of Ophthalmology, Tufts University School of Medicine, Boston, MA 02111, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ajo.2011.08.035","article-title":"Time trends in the incidence and causes of blindness in Israel","volume":"153","author":"Skaat","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in Denmark: Year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/bjophthalmol-2019-314446","article-title":"The Moorfields AMD database report 2: Fellow eye involvement with neovascular age-related macular degeneration","volume":"104","author":"Fasler","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.ophtha.2014.04.026","article-title":"The neovascular age-related macular degeneration database: Report 2: Incidence, management, and visual outcomes of second treated eyes","volume":"121","author":"Liew","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00417-018-4100-z","article-title":"Incidence and risk factors for neovascular age-related macular degeneration in the fellow eye","volume":"256","author":"Bek","year":"2018","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.oret.2020.07.005","article-title":"Morphologic predictors and temporal characteristics of conversion from nonexudative to exudative age-related macular degeneration in the fellow eye","volume":"5","author":"Teo","year":"2021","journal-title":"Ophthalmol. Retina"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jamaophthalmol.2018.2154","article-title":"Incidence of fellow eye involvement in patients with unilateral exudative age-related macular degeneration","volume":"136","author":"Yanagi","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jamaophthalmol.2019.1947","article-title":"Incidence of new choroidal neovascularization in fellow eyes of patients with age-related macular degeneration treated with intravitreal aflibercept or ranibizumab","volume":"137","author":"Parikh","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/aos.15094","article-title":"What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register","volume":"100","author":"Schroeder","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3928\/23258160-20210302-02","article-title":"Characterizing progression to neovascular AMD in fellow eyes of patients treated with intravitreal anti-VEGF injections","volume":"52","author":"Starr","year":"2021","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.ophtha.2021.07.025","article-title":"Diagnostic accuracy of monitoring tests of fellow eyes in patients with unilateral neovascular age-related macular degeneration: Early detection of neovascular age-related macular degeneration study","volume":"128","author":"Sivaprasad","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/IAE.0b013e31819a6154","article-title":"First versus second eye intravitreal ranibizumab therapy for wet AMD","volume":"29","author":"Eldaly","year":"2009","journal-title":"Retina"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000469652","article-title":"Bilateral neovascular age-related macular degeneration: Comparisons between first and second eyes","volume":"238","author":"Chew","year":"2017","journal-title":"Ophthalmologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/IAE.0000000000002768","article-title":"Current concepts and modalities for monitoring the fellow eye in neovascular age-related macular degeneration: An expert panel consensus","volume":"40","author":"Wong","year":"2020","journal-title":"Retina"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-Related Macular Degeneration Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","article-title":"A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact","volume":"117","author":"Gupta","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ajo.2010.06.025","article-title":"Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments","volume":"150","author":"Giani","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3109\/08820538.2011.622337","article-title":"Administration of repeat intravitreal anti-VEGF drugs by retina specialists in an injection-only clinic for patients with exudative AMD: Patient acceptance and safety","volume":"26","author":"Engman","year":"2011","journal-title":"Semin. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sethi, K., Levine, E.S., Roh, S., Marx, J.L., and Ramsey, D.J. (2021). Modeling the impact of COVID-19 on retina clinic performance. BMC Ophthalmol., 21.","DOI":"10.1186\/s12886-021-01955-x"},{"key":"ref_20","unstructured":"Frontz, A.J., and Department of Health and Human Services Office of Inspector General (2021, October 18). An Ophthalmology Clinic in California: Audit of Medicare Payments for Eye Injections of Eylea and Lucentis. March 2021. Report A-09-19-03022, Available online: https:\/\/oig.hhs.gov\/oas\/reports\/region9\/91903022.pdf."},{"key":"ref_21","unstructured":"CPT Editorial Panel (2022, December 08). CPT\u00ae Evaluation and Management (E\/M). E\/M Code Descriptors & Guidelines for 2023. Services Reported Separately. p. 5. American Medical Association. Available online: https:\/\/www.ama-assn.org\/system\/files\/2023-e-m-descriptors-guidelines.pdf."},{"key":"ref_22","unstructured":"Medicare Fee for Service Recovery Audit Program (2022, December 08). U.S. Centers for Medicare & Medicaid Services, Available online: https:\/\/www.cms.gov\/research-statistics-data-and-systems\/monitoring-programs\/medicare-ffs-compliance-programs\/recovery-audit-program."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/PPA.S347713","article-title":"Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: A multi-national qualitative study","volume":"16","author":"Peto","year":"2022","journal-title":"Patient Prefer. Adherence"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/bjophthalmol-2018-313682","article-title":"Visual benefit versus visual gain: What is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA","volume":"104","author":"Tufail","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajo.2021.11.020","article-title":"Correlation of change in central subfield thickness and change in visual acuity in neovascular AMD: Post hoc analysis of VIEW 1 and 2","volume":"238","author":"Nanegrungsunk","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1097\/IAE.0000000000002220","article-title":"Optical coherence tomography, fluorescein angiography, and diagnosis of choroidal neovascularization in age-related macular degeneration","volume":"39","author":"Gualino","year":"2019","journal-title":"Retina"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.survophthal.2012.01.006","article-title":"Evaluation of age-related macular degeneration with optical coherence tomography","volume":"57","author":"Kane","year":"2012","journal-title":"Surv. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1097\/IAE.0000000000000766","article-title":"Optical coherence tomography angiography versus traditional multimodal imaging in assessing the activity of exudative age-related macular degeneration: A new diagnostic challenge","volume":"35","author":"Coscas","year":"2015","journal-title":"Retina"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.oret.2019.03.008","article-title":"Detection of nonexudative choroidal neovascularization and progression to exudative choroidal neovascularization using OCT angiography","volume":"3","author":"Bailey","year":"2019","journal-title":"Ophthalmol. Retina"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/OPTH.S92548","article-title":"Current barriers to treatment for wet age-related macular degeneration (wAMD): Findings from the wAMD patient and caregiver survey","volume":"9","author":"Varano","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Borrelli, E., Battista, M., Vella, G., Grosso, D., Sacconi, R., Querques, L., Zucchiatti, I., Prascina, F., Bandello, F., and Querques, G. (2021). The COVID-19 pandemic has had negative effects on baseline clinical presentation and outcomes of patients with newly diagnosed treatment-na\u00efve exudative AMD. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061265"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00417-020-04955-7","article-title":"Short-term outcomes of patients with neovascular exudative AMD: The effect of COVID-19 pandemic","volume":"258","author":"Borrelli","year":"2020","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0008-4182(05)80074-2","article-title":"Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration","volume":"40","author":"Bakal","year":"2005","journal-title":"Can. J. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"}],"updated-by":[{"DOI":"10.3390\/life13122241","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000}}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/2\/385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T14:15:13Z","timestamp":1754230513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/2\/385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["life13020385"],"URL":"https:\/\/doi.org\/10.3390\/life13020385","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]}}}